NEW YORK, Jan 23 – Phase-1 Molecular Toxicology, a privately held Santa Fe, N.M.–based toxicogenomics company, said Tuesday it has signed an agreement to sell Axon Instruments’ GenePx 4000B microarray scanner along with its toxicogenomic and toxicoproteomic microarrays and software.
The companies will offer the scanner, arrays, and software as a package deal, according to Phase-1 CEO Spencer Farr, who declined to specify how the companies will share revenues.
After looking at most of the scanners on the market, Phase-1 chose Axon’s scanners due to Axon's level of customer service and the instrument quality, Farr said. Phase-1 plans to offer customers pre-calibrated scanners to ensure maximum consistency of results.
" I don’t think most labs yet know about the variability inherently due to scanners,” explained Farr. “If you take a slide and go to most scanner manufacturers, then put it in two different scanners, [the results] can vary by as much as 50 percent. This makes it very difficult for different labs to compare results. These scanners will come pre-loaded with our software, designed specifically for the toxicologist.”
Phase-1 currently markets a selection of rat and human microarrays designed to test compounds for gene and protein expression consistent with toxic reactions in both organisms. The company is currently developing canine and custom microarrays as well.